BR9813015A - Processo para o diagnóstico da doença de alzheimer em um paciente e isoforma anormal de acetilcolinesterase com um padrão de glicosilação alterado - Google Patents

Processo para o diagnóstico da doença de alzheimer em um paciente e isoforma anormal de acetilcolinesterase com um padrão de glicosilação alterado

Info

Publication number
BR9813015A
BR9813015A BR9813015-3A BR9813015A BR9813015A BR 9813015 A BR9813015 A BR 9813015A BR 9813015 A BR9813015 A BR 9813015A BR 9813015 A BR9813015 A BR 9813015A
Authority
BR
Brazil
Prior art keywords
glycosylation pattern
patient
alzheimer
diagnosis
disease
Prior art date
Application number
BR9813015-3A
Other languages
English (en)
Inventor
David Henry Small
Javier Saez-Valero
Gian Sberna
Original Assignee
Univ Melbourne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Melbourne filed Critical Univ Melbourne
Publication of BR9813015A publication Critical patent/BR9813015A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/827—Actinoplanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

<B><MU>PROCESSO PARA O DIAGNóSTICO DA DOENçA DE ALZHEIMER EM UM PACIENTE E ISOFORMA ANORMAL DE ACETILCOLINESTERASE COM UM PADRãO DE GLICOSILAçãO ALTERADO<MV><D> Expõe-se um processo para o diagnóstico da doença de Alzheimer (AD) em um paciente, que compreende as etapas de: (1) proporcionar uma amostra de um fluido corpóreo apropriado proveniente do dito paciente; (2) detectar a presença de acetilcolinesterase (AChE) com um padrão de glicosilação alterado na dita amostra. Estabeleceu-se que aproximadamente 75-95% da AChE na CSF de pacientes de AD aglutina-se a Concanavalin (Con A) ou aglutinina de gérmen de trigo (WGA) mas com especificidade diferente para cada um. Conseq³entemente, a fim de se identificar o padrão de glicosilação de AChE na amostra, determina-se a aglutinação a Con A, então determina-se a aglutinação a WGA, e calcula-se uma proporção. A proporção é característica do padrão de glicosilação. De acordo com uma concretização alternativa da invenção, utiliza-se um padrão de glicosilação alterado para detectar a sua presença.
BR9813015-3A 1997-09-24 1998-09-24 Processo para o diagnóstico da doença de alzheimer em um paciente e isoforma anormal de acetilcolinesterase com um padrão de glicosilação alterado BR9813015A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPO9432A AUPO943297A0 (en) 1997-09-24 1997-09-24 Diagnostic test for alzheimer's disease
PCT/AU1998/000809 WO1999015695A1 (en) 1997-09-24 1998-09-24 Diagnostic test for alzheimer's disease

Publications (1)

Publication Number Publication Date
BR9813015A true BR9813015A (pt) 2000-08-15

Family

ID=3803714

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9813015-3A BR9813015A (pt) 1997-09-24 1998-09-24 Processo para o diagnóstico da doença de alzheimer em um paciente e isoforma anormal de acetilcolinesterase com um padrão de glicosilação alterado

Country Status (11)

Country Link
US (1) US6461831B1 (pt)
EP (1) EP1017845B1 (pt)
JP (1) JP2001517456A (pt)
AT (1) ATE323781T1 (pt)
AU (1) AUPO943297A0 (pt)
BR (1) BR9813015A (pt)
CA (1) CA2304949A1 (pt)
DE (1) DE69834263D1 (pt)
HU (1) HUP0003684A3 (pt)
IL (1) IL135211A0 (pt)
WO (1) WO1999015695A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL130225A0 (en) * 1999-05-31 2000-06-01 Yissum Res Dev Co Novel uses of antibodies against ache and peptides thereof
US20020150878A1 (en) * 2001-01-23 2002-10-17 Small David Henry Method for the diagnosis of Alzheimer's Disease and other prion related disorders
AU2003299730B2 (en) * 2002-12-20 2009-04-02 Momenta Pharmaceuticals, Inc. Glycan markers for diagnosing and monitoring disease
GB2404734A (en) * 2003-08-05 2005-02-09 Secr Defence A method of screening a sample for abnormally glycosylated and/or expressed proteins
US20060094064A1 (en) * 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
ES2411455T3 (es) * 2003-11-19 2013-07-05 Rules-Based Medicine, Inc. Procedimiento para el diagnóstico y la monitorización de la enfermedad de Alzheimer
US20050272643A1 (en) * 2004-06-08 2005-12-08 Windber Research Institute Removal of serum albumin from human serum or plasma
US7851172B2 (en) 2006-07-25 2010-12-14 University Of Kentucky Research Foundation Biomarkers of mild cognitive impairment and alzheimer's disease
US20100124756A1 (en) * 2008-10-10 2010-05-20 Sandip Ray Collection of biomarkers for diagnosis and monitoring of alzheimer's disease in body fluids
US8355927B2 (en) 2010-11-05 2013-01-15 Genomind, Llc Neuropsychiatric test reports
US20110237537A1 (en) * 2009-05-29 2011-09-29 Lombard Jay L Methods for assessment and treatment of mood disorders via single nucleotide polymorphisms analysis
ES2581178T3 (es) 2009-07-29 2016-09-01 Pharnext Nuevas herramientas de diagnóstico para enfermedad de Alzheimer
US20110202284A1 (en) * 2010-02-10 2011-08-18 Mcreynolds Cristopher Novel groups of biomarkers for diagnosing alzheimer's disease
ES2395063B1 (es) * 2011-03-04 2014-02-07 Universidad Miguel Hernández De Elche Método para determinar la enfermedad de Alzheimer mediante la detección de glicoproteínas portadoras del glicoepítopo HNK-1
EP2836844B1 (en) 2012-04-13 2017-08-16 Oasis Diagnostics Corporation Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595883A (en) * 1990-06-01 1997-01-21 E. R. Squibb & Sons, Inc. Method of diagnosing alzheimer's disease by measuring acetylcholinesterase activity in ocular fluid
US5200324A (en) * 1990-09-04 1993-04-06 E. R. Squibb & Sons, Inc. Method of diagnosing senile dementia of the Alzheimer type
CA2048700A1 (en) 1990-09-04 1992-03-05 Dasakumar S. Navaratnam Method for diagnosing senile dementia of the alzheimer type

Also Published As

Publication number Publication date
EP1017845A4 (en) 2003-07-02
IL135211A0 (en) 2001-05-20
HUP0003684A2 (hu) 2001-02-28
EP1017845B1 (en) 2006-04-19
EP1017845A1 (en) 2000-07-12
AUPO943297A0 (en) 1997-10-16
DE69834263D1 (de) 2006-05-24
CA2304949A1 (en) 1999-04-01
ATE323781T1 (de) 2006-05-15
US6461831B1 (en) 2002-10-08
JP2001517456A (ja) 2001-10-09
HUP0003684A3 (en) 2003-04-28
WO1999015695A1 (en) 1999-04-01

Similar Documents

Publication Publication Date Title
BR9813015A (pt) Processo para o diagnóstico da doença de alzheimer em um paciente e isoforma anormal de acetilcolinesterase com um padrão de glicosilação alterado
Müller-Thomsen et al. Detecting depression in Alzheimer’s disease: evaluation of four different scales
Brenner et al. Distribution, determinants, and prognostic value of γ-glutamyltransferase for all-cause mortality in a cohort of construction workers from southern Germany
Thompson et al. The discrepancy between emotional vs. rational estimates of body size, actual size, and ideal body ratings: Theoretical and clinical implications
Nasrallah et al. Neurological soft signs in manic patients: A comparison with schizophrenic and control groups
HUP0301020A2 (hu) Konformációs betegségek korai diagnosztikája
WO2004103150A3 (en) Apparatus and method for risk stratification of patients with chest pain of suspected cardiac origin
Ramsay et al. Determination of oligosaccharides and glycolipids in amniotic fluid by electrospray ionisation tandem mass spectrometry: in utero indicators of lysosomal storage diseases
McDougall et al. Psychometric properties of the Clinical Dementia Rating—Sum of Boxes and other cognitive and functional outcomes in a prodromal Alzheimer’s disease population
BR0109915A (pt) Teste de diagnóstico para doença de alzheimer
Chen et al. Cathepsin B, α2‐macroglobulin and cystatin levels in gingival crevicular fluid from chronic periodontitis patients
JP2001517456A5 (pt)
Pocekay et al. A cross‐sectional study of musculoskeletal symptoms and risk factors in semiconductor workers
Gustafsson et al. Altered relation between granulocyte elastase and α‐2‐macroglobulin in gingival crevicular fluid from sites with periodontal destruction
Landi et al. Functional status and clinical correlates in cognitively impaired community-living older people
Lundy et al. Evaluation of major parotid glycoproteins in patients with burning mouth syndrome
Martinez et al. Effects of pharmacological therapy on anthropometric and biochemical status of male and female institutionalized psychiatric patients.
ATE145673T1 (de) Verfahren zur diagnostizierung von menschlicher grippe und in position 4 modifizierte chromogene n-acetylneuraminsäure substrate zur verwendung in diesen verfahren
JENKINSON et al. Measurement of health status in patients with chronic illness: comparison of the Nottingham health profile and the general health questionnaire
Madej‐Pilarczyk et al. Progeroid syndrome with scleroderma‐like skin changes associated with homozygous R435C LMNA mutation
Swann Chronic ethanol and (Na+-K+)-adenosine triphosphate: apparent adaptation in cation binding and enzyme conformation.
Weiss et al. Antigens of powdered pearl-oyster shell causing hypersensitivity pneumonitis
Walsh et al. Correlations among the Reiss Screen, the adaptive behavior scale Part II, and the aberrant behavior checklist
POSER et al. Cerebrospinal fluid free cholesterol as index of activity of multiple sclerosis and allied diseases
Thind et al. Signification of high density and total cholesterol and triglycerides in acute myocardial infarction—a case-control study

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: MONASH UNIVERSITY (AU)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A E 10A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 1986 DE 27/03/2009.